

Lucian da Silva Viana, Marcell de Oliveira Santos, Rejane de Souza Reis, Paulo A. Faria, Beatriz de Camargo

## INTRODUCTION


Renal tumors accounts for 6% of all childhood tumors and 90% are nephroblastoma (Wilms tumor)<sup>1,2</sup>. Cooperative groups has been responsible for significant improvements in outcome of children with cancer<sup>3,4</sup>. The Brazilian Wilms tumor Study group (GCBTTW) was formed in 1978 and since 2001 has participated at the International Society of Pediatric Oncology (SIOP) Renal tumor study group<sup>5,6</sup>. The participation on clinical trials improves not only individual treatment but also the infrastructure of the institution<sup>7</sup>.

## AIM

To analyse clinical features of children with renal tumors in Brazil and its access to cooperative groups through Hospital-Based Cancer Registry (HBCR) and patients registered at the GCBTTW.

## METHODOLOGY

Descriptive study of children (0-14 years old) with renal tumors (C64.9), register at the GCBTTW and HBCR during the period from 2001 e 2009. One thousand four hundred and fifty nine cases (103 hospitais) from 22 states and Federal District were obtained from the HBCR (<https://irhc.inca.gov.br/RHCNet/>) and four hundred ninety eight cases register at the GCBTTW from 40 hospitais localized from 14 states (Figure 1). Statistical analyse will be done using SPSS 20 software.



**Figure 1** – Local place of hospital of both data base (HBCR-GCBTTW).  
 ○ HBCR – Hospital-Based Cancer Registry.  
 ☆ GCBTTW – Grupo Cooperativo Brasileiro para Tratamento de Tumor de Wilms.

## PRELIMINARY RESULTS

Among 103 HBCR, 24.2% had register cases at GCBTTW. HBCR was not available in 15 institutions that participate at GCBTTW. Clinical features were similar between both groups (Table 1).

**Table 1** – Clinical features of children with renal tumors in Brazil (2001-2009).

	HBCR		GCBTTW	
	n	%	n	%
<b>Gender</b>				
Male	703	48.2	244	49.0
Female	756	51.8	253	50.8
No information	-	-	1	0.2
<b>Age group</b>				
0-4	1065	73.0	362	72.7
5-9	313	21.5	103	20.7
10-14	81	5.5	20	4.0
No information	-	-	13	2.6
<b>Previous treatment</b>				
No	1340	91.9	490	98.4
Yes	101	6.9	8	1.6
No information	18	1.2	-	-
<b>International Classification of Childhood Cancer</b>				
Via	1357	93.00	494	99.2
Vib	76	5.2	1	0.2
Vic	26	1.8	2	0.4
No information	-	-	1	0.2
<b>Stage</b>				
I	-	-	142	28.5
II	-	-	111	22.3
III	-	-	104	20.9
IV	-	-	62	12.4
V	-	-	15	3.0
No information	-	-	64	12.8
<b>Metastases</b>				
No	-	-	435	87.3
Yes	-	-	63	12.7
<b>TOTAL</b>	<b>1459</b>		<b>498</b>	

HBCR – Hospital-Based Cancer Registry.

GCBTTW – Brazilian Wilms tumor Study group.

## NEXT STEPS

To analyze the overall registration rates in the GCBTTW among patients from the different Brazilian regions according to age, gender, and stage.

## REFERENCES

- Little J. Introduction. In: Little J. Epidemiology of childhood cancer. Lyon: International Agency for Research on Cancer: World Health Organization. 1999.
- Parkin DM, Kramárová E, Draper GJ, et al., editors. International incidence of childhood cancer, International Agency for Research on Cancer, International Association of Cancer Registries Vol. II. Lyon: IARC Scientific Publications. 1998.
- Gutierrez JC, Cheung MC, Zhuge Y, Koniaris L G, Sola JE. Does Children's Oncology Group hospital membership improve survival for patients with neuroblastoma or Wilms tumor? *Pediatr. Blood Cancer.* 2010;55:621-628.
- Liu L, Krailo M, Reaman GH, Bernstein L. Childhood cancer patients' access to cooperative group cancer programs: A populationbased study. *Cancer.* 2003;97:1339-45.
- De Camargo B, Franco EL. Single-dose versus fractionated-dose dactinomycin in the treatment of wilms' tumor. Preliminary results of a clinical trial. *Cancer.* 1991;67:2990-6.
- Pritchard-Jones K, Bergeron C, De Camargo B, et al. Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomized controlled trial. *Lancet Oncology.* 2015;19(86):1156-64.
- Denburg A, Rodriguez-Galindo C, Joffe S. Clinical Trials Infrastructure as a Quality Improvement Intervention in Low- and Middle-Income Countries. *Am J Bioeth.* 2016 Jun;16(6):3-11.